This US-based key opinion leader (KOL) provides insights on the current treatment strategies for chronic spontaneous urticaria (CSU). The KOL discusses the challenges in disease awareness and diagnosis, emphasizing the importance of understanding pathomechanisms and the need for more effective treatments. The KOL highlights the role of biologics like omalizumab and dupilumab, and the potential impact of new therapies such as remibrutinib and c-KIT inhibitors on the treatment landscape. The KOL also addresses the compliance issues, the significance of patient-reported outcomes, and the economic considerations in treatment choices. Additionally, the KOL commented on the future of CSU management, including the role of biomarkers and the potential for new therapies to replace existing ones.

This interview was conducted on 01 August, 2025.

If you are a Datamonitor Healthcare client, you may access the interview from our KOL Insight channel.

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.